The immune system is characterized by sophisticated control of its activation: there is an intricate series of immunopotentiating and immunosuppression cells and molecules that work in a balanced way. However, this equilibrium is altered in pathological situations such as cancer. The development of biomolecules, monoclonal antibodies, peptides, proteins and small molecules capable of influencing these control systems is revolutionizing the development of drugs and therapeutic alternatives.
Our line of research focuses on the development of immunopotentiation strategies based on the development of:
New inhibitors of these control points such as TGF-beta cytokines, IL-10 and Foxp3 and NFAT transcription factors.
New combinations of immunostimulants, adjuvants, monoclonal antibodies and antigens than have been tested in preclinical models.
Antitumor therapies based on the transfer of genetically modified T lymphocytes.
New signal pathways that are key to activating immune responses.
The group has worked in recent years on identifying inhibitors of key molecules in the regulation of the immune system, such as TGF-beta cytokines, IL-10 and, more recently, transcription factors Foxpt and NFAT, which have been demonstrated in in vitro models and in vivo tumor models. At the same time, we have worked on the development of cytokine stabilization and targeting strategies that may have significant therapeutic potential by reducing the toxic effects of systemic administration. Combinations of immunostimulants, adjuvants, monoclonal antibodies and antigens have been tested in preclinical models. In the same way, the group is working actively on the design of strategies to modify gene expression of chimeric molecules, cytokines and specific inhibitors that may provide the transferred cells with greater antitumor capability.
This area of work is being transformed through new partnership agreements with biopharmaceutical companies interested in carrying out clinical trials in collaboration with the Clínica Universidad de Navarra.